David Stamler

David Stamler

Chief Executive Officer at ALTERITY THERAPEUTICS

Net worth: 12 344 $ as of 31/05/2026

65 year
Health Technology
Consumer Services
Commercial Services

Profile

David A. Stamler is Chief Executive Officer, MD & Director at Alterity Therapeutics Ltd. since 2025.
Former roles include Vice President-Clinical Development & Therapeutic at Teva Pharmaceutical Industries Ltd. from 2015 to 2017, Chief Medical Officer at Auspex Pharmaceuticals, Inc. from 2011 to 2015, Chief Medical Officer & Senior Vice President at XenoPort, Inc. from 2008 to 2010, Chief Scientific Officer & Head-Drug Development at Prestwick Pharmaceuticals, Inc. from 2005 to 2008, Senior Global Project Leader-CNS Diseases at Fujisawa Pharmaceutical Co., Ltd. from 2003 to 2005, Vice President-Research & Development at Fujisawa Healthcare, Inc. from 2003 to 2005, Vice President- Clinical Research Center at Astellas Research Institute of America LLC from 2000 to 2003, Director-Clinical Research at Abbott Laboratories from 1993 to 1997.
Education includes undergraduate studies at The University of Chicago and a doctorate from Pritzker School of Medicine.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
15/04/2026 1,904,862 ( 0.02% ) 12 344 $ 31/05/2026

David Stamler active positions

CompaniesPositionStart
ALTERITY THERAPEUTICS Chief Executive Officer 07/01/2021

Former positions of David Stamler

CompaniesPositionEnd
TEVA PHARMACEUTICAL INDUSTRIES LIMITED Corporate Officer/Principal 01/01/2017
AUSPEX PHARMACEUTICALS INC Chief Tech/Sci/R&D Officer 05/05/2015
XENOPORT, INC. Chief Tech/Sci/R&D Officer 19/11/2010
Chief Tech/Sci/R&D Officer 01/01/2008
Corporate Officer/Principal 01/01/2005
See the detail of David Stamler's experience

Training of David Stamler

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

61

1st degree connections

11

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies11

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Fujisawa Healthcare, Inc.

Commercial Services

Health Technology

Consumer Services

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!